The RE-SPECT ESUS study (Randomized Evaluation in Secondary stroke PrEvention Comparing the Thrombin inhibitor dabigatran etexilate versus acetylsalicylic acid (ASA) in Embolic
Stroke of Undetermined Source) aims to include 6,000 patients from study sites in Asia, Europe, North and South America.
The FilterWire EZ Embolic
Protection System is designed to capture plaque debris that may be released during a procedure, preventing it from traveling to the brain, where it could cause a stroke.
It is intuitive to use and offers some dramatic advantages over traditional embolic
He now uses both abciximab and an embolic
protection device in high-risk patients.
ARCHeR 3 did not include 1-year data; the study was designed simply to establish that the newer embolic
protection devices were equivalent to the first-generation versions used in ARCHeR 2.
We demonstrated that the short amount of time between embolization and resection precluded the development of any inflammatory or stromal response to either the embolic
material or the necrotic foci in either the ethanol- orPVA-embolized cases.
Indeed, our three platforms of procedural accessory devices address the three most pressing clinical needs in the rapidly growing evolution of transcatheter aortic valve replacement (TAVR) therapies: specifically, (1) a dire need for nonsurgical, large-hole (>12 Fr) access and closure technologies, (2) aortic embolic
protection devices for prevention of stroke and other ischemic complications, and (3) prevention of contrast nephropathy.
LC Bead LUMI is a next generation development of the LC Bead embolic
It is clear from the published studies in TAVI that embolic
events do occur and need to be minimized.
In addition to providing embolic
protection and minimizing arterial injury, this promising technology is aimed at providing an effective and uniform drug delivery mechanism for next generation drug eluting stents.
A carotid stent system approved for use with an embolic
protection system, for patients with carotid artery disease who are at high risk for carotid endarterectomy and who meet certain criteria.
This patent gives GeNeuron an important platform for the delivery of liquid embolic
agents for the occlusion of saccular aneurysms," commented Matthew Hantzmon, president of GeNeuron Therapeutics.